EDIT·Nasdaq·US

Editas

Editas is a clinical stage genome editing company that develops genomic medicines to treat serious diseases using CRISPR technology, with its lead product candidate reni-cel for sickle cell disease and transfusion-dependent beta thalassemia, and it also licenses its gene editing platform to pharmaceutical and biotechnology company partners such as Bristol Myers Squibb, Vertex Pharmaceuticals, and Vor Biopharma.

Source: SEC 10-K Feb 28, 2024

Create free account

Recent Activity

Updated Oct 17, 2026

–Editas Medicine announced poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and its participation in an upcoming investor conference.

Past updates are part of the Pro plan.

Thematic Position

EDIT

Healthcare Innovation

Biotechnology

Gene Therapy & EditingLeader

Relationship Groups

Partners1

Licensing4

Competitors21

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

6 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

armed conflictpolitical instabilitytariff

Ukraine-Russia conflict cited as political instability risk to foreign operations

SEC 10-KMar 9, 2026

The full regulatory passage is part of the Pro plan.

5 more · Regulatory and geopolitical insights are part of the Pro plan.